JP2010500291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500291A5 JP2010500291A5 JP2009523112A JP2009523112A JP2010500291A5 JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5 JP 2009523112 A JP2009523112 A JP 2009523112A JP 2009523112 A JP2009523112 A JP 2009523112A JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- csfr
- csf
- pharmaceutical composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 33
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 33
- 208000019693 Lung disease Diseases 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 230000008595 infiltration Effects 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 229940124630 bronchodilator Drugs 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006904378A AU2006904378A0 (en) | 2006-08-11 | Treatment and prophylaxis of pulmonary disease conditions | |
| AU2006904378 | 2006-08-11 | ||
| PCT/AU2007/001127 WO2008017126A1 (en) | 2006-08-11 | 2007-08-10 | Treatment of pulmonary disease conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500291A JP2010500291A (ja) | 2010-01-07 |
| JP2010500291A5 true JP2010500291A5 (enExample) | 2010-09-24 |
| JP5235881B2 JP5235881B2 (ja) | 2013-07-10 |
Family
ID=39032559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523112A Active JP5235881B2 (ja) | 2006-08-11 | 2007-08-10 | 肺疾患病態の処理 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8574572B2 (enExample) |
| EP (2) | EP2526959B1 (enExample) |
| JP (1) | JP5235881B2 (enExample) |
| AU (1) | AU2007283463B2 (enExample) |
| CA (1) | CA2661446C (enExample) |
| DK (1) | DK2056858T3 (enExample) |
| ES (1) | ES2506065T3 (enExample) |
| NZ (1) | NZ574285A (enExample) |
| PL (1) | PL2056858T3 (enExample) |
| WO (1) | WO2008017126A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013500993A (ja) * | 2009-07-31 | 2013-01-10 | ジェネンテック， インコーポレイテッド | Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害 |
| DK2477656T3 (en) * | 2009-09-15 | 2017-06-26 | Csl Ltd | TREATMENT OF NEUROLOGICAL CONDITIONS |
| TWI600759B (zh) * | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| CA2838246C (en) | 2011-06-13 | 2018-07-10 | Csl Limited | Antibodies against g-csfr and uses thereof |
| EP3298402A1 (en) * | 2015-05-18 | 2018-03-28 | The University of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
| JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物 |
| PL3717011T3 (pl) * | 2017-11-29 | 2023-03-27 | Csl Limited | Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| KR102887037B1 (ko) * | 2018-12-04 | 2025-11-18 | 씨에스엘 이노베이션 피티와이 엘티디 | 호중구 질환을 치료하는 방법 |
| CN115768475A (zh) * | 2020-06-04 | 2023-03-07 | Csl创新私人有限公司 | 治疗或预防急性呼吸窘迫综合征的方法 |
| WO2025007195A1 (en) | 2023-07-05 | 2025-01-09 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| BR9206313A (pt) | 1991-07-25 | 1995-04-11 | Idec Pharma Corp | Anticorpos recombinantes para terapia humana. |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| DK1542528T3 (da) * | 2002-08-23 | 2010-02-01 | Inst Medical W & E Hall | Fremgangsmåde til behandling og profylakse |
| JP5036557B2 (ja) * | 2005-01-13 | 2012-09-26 | グラクソ グループ リミテッド | 抗炎症活性デクラジノシル−マクロライド |
| WO2006077504A2 (en) | 2005-01-18 | 2006-07-27 | Koninklijke Philips Electronics N.V. | An algorithm for growing 4-connected cores in image segmentation |
| US20090007281A1 (en) * | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
-
2007
- 2007-08-10 EP EP12174059.1A patent/EP2526959B1/en not_active Not-in-force
- 2007-08-10 EP EP07784767.1A patent/EP2056858B1/en active Active
- 2007-08-10 AU AU2007283463A patent/AU2007283463B2/en not_active Ceased
- 2007-08-10 NZ NZ574285A patent/NZ574285A/en not_active IP Right Cessation
- 2007-08-10 US US12/377,256 patent/US8574572B2/en not_active Expired - Fee Related
- 2007-08-10 JP JP2009523112A patent/JP5235881B2/ja active Active
- 2007-08-10 ES ES07784767.1T patent/ES2506065T3/es active Active
- 2007-08-10 PL PL07784767T patent/PL2056858T3/pl unknown
- 2007-08-10 CA CA2661446A patent/CA2661446C/en active Active
- 2007-08-10 WO PCT/AU2007/001127 patent/WO2008017126A1/en not_active Ceased
- 2007-08-10 DK DK07784767.1T patent/DK2056858T3/da active
-
2013
- 2013-10-01 US US14/042,931 patent/US9376682B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500291A5 (enExample) | ||
| JP2005530490A5 (enExample) | ||
| JP2011500003A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2018126141A5 (enExample) | ||
| JP2007505627A5 (enExample) | ||
| JP2009539367A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2009525764A5 (enExample) | ||
| JP2008546390A5 (enExample) | ||
| JP2010528601A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2018510621A5 (enExample) | ||
| JP2020500929A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| Kay et al. | Eosinophils and interleukin-5: the debate continues | |
| JP2011518886A5 (enExample) | ||
| JP2015511625A5 (enExample) | ||
| JP2014504857A5 (enExample) | ||
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| WO2017004499A1 (en) | Compositions and methods for the treatment of viral infection | |
| JP2010540649A5 (enExample) | ||
| JP2006158399A5 (ja) | 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤 | |
| JP2016533190A5 (enExample) |